Papers
4
Total Citations
122
H-Index
4
About
No biography available yet.
Research Focus
Cancer4 · 122 citations
Surgery4 · 122 citations
Medicine4 · 122 citations
Internal medicine4 · 122 citations
Chemotherapy2 · 75 citations
Oncology2 · 75 citations
Pembrolizumab2 · 75 citations
Immunotherapy2 · 75 citations
Neoadjuvant therapy2 · 75 citations
Paclitaxel2 · 75 citations
Stage (stratigraphy)2 · 75 citations
Cisplatin1 · 62 citations
Key Achievements
4
H-Index
4
Papers
122
Total Citations
31
Avg Citations/Paper
🏆 Most Cited Paper
Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)
62 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 25
🏛 Institutions: Tianjin Medical University Cancer Institute and Hospital
Top Papers
- 1
- 2
- 3
- 4
Key Collaborators
HJHongjing Jiang4 shared papersJYJie Yue3 shared papersXDXiaofeng Duan3 shared papersCCChuangui Chen3 shared papersXSXiaobin Shang3 shared papersCZChen Zhang2 shared papersBMBin Meng2 shared papersWZW. Zhang1 shared papersLLL. Liu1 shared papersGZGang Zhao1 shared papersGZGang Zhao1 shared papersXRXiubao Ren1 shared papersRLRunmei Li1 shared papersXRXiubao Ren1 shared papersLGLei Gong1 shared papersLLLiang Liu1 shared papersCZChao Zhang1 shared papersXDXingyu Duan1 shared papersFLFei Liang1 shared papersJYJ. Yue1 shared papers
Not generated yet